Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
CNS Stimulants: Psychedelic Agents01:22

CNS Stimulants: Psychedelic Agents

1.1K
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
1.1K
Drug Therapy01:28

Drug Therapy

445
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
445
Hallucinogens and Psychedelics01:27

Hallucinogens and Psychedelics

1.1K
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
1.1K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

699
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
699
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

2.1K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Life-course stress exposure and cognitive decline in middle-aged and older Chinese adults: The role of sex differences and educational protection.

Social science & medicine (1982)·2026
Same author

Perinatal Fluoxetine Exposure Has No Major Effect on Myelin-Associated Glycoprotein and Myelin Basic Protein Levels in Auditory Brain Regions.

Biology·2025
Same author

Effects of early-life stress on social functioning in depression: A systematic review and meta-analysis of mouse and rat studies.

Neuroscience and biobehavioral reviews·2025
Same author

Perinatal fluoxetine exposure does not impair cognition in offspring.

Behavioural brain research·2025
Same author

Animal models of early-onset hearing loss: A systematic review of the effects on cognition, social behavior, vocalization, and neurobiological mechanisms.

Hearing research·2025
Same author

Maternal SSRI Use During Pregnancy: Links Between Gut Microbiome, Offspring Behaviour, and Brain Transcriptomics.

Current topics in behavioral neurosciences·2025

Related Experiment Video

Updated: Apr 28, 2026

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
07:58

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Published on: February 24, 2023

1.0K

Psychedelics: Future Therapeutics in Major Depression?

Berend Olivier1,2,3, Jocelien D A Olivier4

  • 1Department of Psychopharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands. b.olivier@rug.nl.

Advances in Experimental Medicine and Biology
|April 26, 2026
PubMed
Summary

New psychedelic drugs like psilocybin and esketamine offer rapid and long-lasting relief for major depressive disorder (MDD) and treatment-resistant depression (TRD). These novel treatments represent a significant advancement in psychiatric care, addressing unmet needs for effective depression therapies.

Keywords:
5-HT2A-receptorAntidepressantsAyahuascaDissociationEfficacyGlutamatergic neurotransmissionKetamineMajor depressive disorderNMDA-receptor antagonistPsilocybinPsychedelicsPsychoplastinogensSafetyTolerabilityTreatment-resistant depression

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.0K
HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
07:30

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

6.4K

Related Experiment Videos

Last Updated: Apr 28, 2026

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
07:58

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Published on: February 24, 2023

1.0K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.0K
HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
07:30

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

6.4K

Area of Science:

  • Psychiatry and Pharmacology
  • Neuroscience of Depression
  • Psychedelic Research

Background:

  • Major depressive disorder (MDD) and treatment-resistant depression (TRD) are prevalent, causing significant suffering and economic burden.
  • Conventional antidepressants (SSRIs, SNRIs) have limited efficacy, with up to 30% of patients not responding, leading to TRD.
  • Intense research has focused on novel pharmacological interventions for depression.

Purpose of the Study:

  • To review clinical developments of psilocybin and esketamine for major depression disorders.
  • To highlight the emergence of fast-onset antidepressants for MDD and TRD.
  • To discuss challenges and advancements in research methodologies for psychedelic therapies.

Main Methods:

  • Review of clinical developments and marketing authorizations for psilocybin and esketamine.
  • Analysis of the mechanisms underlying the rapid and sustained antidepressant effects of psychedelics.
  • Discussion of methodological challenges in psychedelic research, particularly 'blind' study designs.

Main Results:

  • Psilocybin (typical psychedelic) and esketamine (atypical psychedelic) have emerged as novel therapeutic options.
  • Both drug classes demonstrate fast onset and long-lasting antidepressant effects, distinct from conventional treatments.
  • These novel agents activate downstream cortical processes contributing to sustained mood improvement.

Conclusions:

  • The development of fast-onset antidepressants marks a significant breakthrough in treating major psychiatric disorders.
  • Psychedelic therapies offer a promising alternative for patients with MDD and TRD.
  • Further research is needed to refine methodologies and fully understand the mechanisms of these novel treatments.